Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors — elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle — are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes.
We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups.
The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin.
Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.
Type 2 diabetes mellitus, formerly called non-insulin-dependent diabetes mellitus, is a serious, costly disease affecting approximately 8 percent of adults in the United States.1 Treatment prevents some of its devastating complications2,3 but does not usually restore normoglycemia or eliminate all the adverse consequences. The diagnosis is often delayed until complications are present.4 Since current methods of treating diabetes remain inadequate, prevention is preferable. The hypothesis that type 2 diabetes is preventable5,6is supported by observational studies and two clinical trials of diet, exercise, or both in persons at high risk for the disease7,8 but not by studies of drugs used to treat diabetes.5
The validity of generalizing the results of previous prevention studies is uncertain.9 Interventions that work in some societies may not work in others, because social, economic, and cultural forces influence diet and exercise. This is a special concern in the United States, where there is great regional and ethnic diversity in lifestyle patterns and where diabetes is especially frequent in certain racial and ethnic groups, including American Indians, Hispanics, African Americans, Asians, and Pacific Islanders.10
The Diabetes Prevention Program Research Group conducted a large, randomized clinical trial involving adults in the United States who were at high risk for the development of type 2 diabetes. The study was designed to answer the following primary questions: Does a lifestyle intervention or treatment with metformin, a biguanide antihyperglycemic agent, prevent or delay the onset of diabetes? Do these two interventions differ in effectiveness? Does their effectiveness differ according to age, sex, or race or ethnic group?
We conducted a clinical trial involving persons at 27 centers who were at high risk for diabetes. The methods have been described in detail elsewhere,6 and the protocol is available at https://dppos.bsc.gwu.edu/. The institutional review board at each center approved the protocol, and all participants gave written informed consent.
Eligibility criteria included an age of at least 25 years, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 24 or higher (22 or higher in Asians), and a plasma glucose concentration of 95 to 125 mg per deciliter (5.3 to 6.9 mmol per liter) in the fasting state (≤125 mg per deciliter in the American Indian clinics) and 140 to 199 mg per deciliter (7.8 to 11.0 mmol per liter) two hours after a 75-g oral glucose load. These concentrations are elevated but are not diagnostic of diabetes according to the 1997 criteria of the American Diabetes Association.11 Before June 1997, the criterion for plasma glucose in the fasting state was 100 to 139 mg per deciliter (5.6 to 7.7 mmol per liter), or ≤139 mg per deciliter in the American Indian clinics. Eligible persons were excluded if they were taking medicines known to alter glucose tolerance or if they had illnesses that could seriously reduce their life expectancy or their ability to participate in the trial. Recruitment was designed to enroll approximately half the participants from racial or ethnic minority groups. A four-step screening and recruitment process was developed to identify eligible participants.6,12,13
Eligible participants were randomly assigned to one of three interventions: standard lifestyle recommendations plus metformin (Glucophage) at a dose of 850 mg twice daily, standard lifestyle recommendations plus placebo twice daily, or an intensive program of lifestyle modification. The study initially included a fourth intervention, troglitazone, which was discontinued in 1998 because of the drug's potential liver toxicity.6 The results in the troglitazone group are not reported here.
Treatment with metformin was initiated at a dose of 850 mg taken orally once a day, with placebo tablets also given once a day initially. At one month, the dose of metformin was increased to 850 mg twice daily, unless gastrointestinal symptoms warranted a longer titration period. The initiation of treatment with half a tablet was optional. Adherence to the treatment regimen was assessed quarterly on the basis of pill counts and structured interviews. The standard lifestyle recommendations for the medication groups were provided in the form of written information and in an annual 20-to-30-minute individual session that emphasized the importance of a healthy lifestyle. Par ticipants were encouraged to follow the Food Guide Pyramid14 and the equivalent of a National Cholesterol Education Program Step 1 diet,15 to reduce their weight, and to increase their physical activity.
The goals for the participants assigned to the intensive lifestyle intervention were to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy low-calorie, low-fat diet and to engage in physical activity of moderate intensity, such as brisk walking, for at least 150 minutes per week. A 16-lesson curriculum covering diet, exercise, and behavior modification was designed to help the participants achieve these goals. The curriculum, taught by case managers on a one-to-one basis during the first 24 weeks after enrollment, was flexible, culturally sensitive, and individualized. Subsequent individual sessions (usually monthly) and group sessions with the case managers were designed to reinforce the behavioral changes.
The primary outcome was diabetes, diagnosed on the basis of an annual oral glucose-tolerance test or a semiannual fasting plasma glucose test, according to the 1997 criteria of the American Diabetes Association: a value for plasma glucose of 126 mg per deciliter (7.0 mmol per liter) or higher in the fasting state or 200 mg per deciliter (11.1 mmol per liter) or higher two hours after a 75-g oral glucose load.11 In addition to the semiannual measurements, fasting plasma glucose was measured if symptoms suggestive of diabetes developed. The diagnosis required confirmation by a second test, usually within six weeks, according to the same criteria. If diabetes was diagnosed, the participants and their physicians were informed and glucose-tolerance tests were discontinued, but fasting plasma glucose was measured every six months, with glycosylated hemoglobin measured annually. As long as the fasting plasma glucose concentration was less than 140 mg per deciliter, participants were asked to monitor their blood glucose and to continue their assigned study treatment. If the fasting plasma glucose concentration reached or exceeded 140 mg per deciliter, the study medication was discontinued and the participant was referred to his or her physician for treatment. Measurements of glucose and glycosylated hemoglobin (HbA1c) were performed centrally. All tests were performed without interrupting the assigned treatment, except that placebo or metformin was not taken on the morning of the test. The investigators and the participants were unaware of the results of these measurements and were informed only if the results exceeded the specified threshold for a change in the treatment.
Self-reported levels of leisure physical activity were assessed annually with the Modifiable Activity Questionnaire.16 The physical-activity level was calculated as the product of the duration and frequency of each activity (in hours per week), weighted by an estimate of the metabolic equivalent of that activity (MET) and summed for all activities performed, with the result expressed as the average MET-hours per week for the previous year. Usual daily caloric intake during the previous year, including calories from fat, carbohydrate, protein, and other nutrients, was assessed at base line and at one year with the use of a modified version of the Block food-frequency questionnaire.17
STATISTICAL ANALYSIS AND EARLY CLOSURE
Random treatment assignments were stratified according to the clinical center. Assignments to metformin and placebo were double-blinded. The study design and analysis followed the intention-to-treat principle. Nominal (unadjusted) P values and confidence intervals are reported.
The blinded treatment phase was terminated one year early, in May 2001, on the advice of the data monitoring board, on the basis of data obtained through March 31, 2001, the closing date for this report. By then, we had obtained evidence of efficacy on the basis of 65 percent of the planned person-years of observation. To maintain a type I error level of 0.05 for significance in pairwise comparisons of the risk of diabetes between groups, with adjustment for repeated interim analyses, the group-sequential log-rank test18 required a P value of less than 0.0159. For pairwise comparisons of other outcomes, a Bonferroni-adjusted criterion of P<0.0167 was used. The study design provided 90 percent power to detect a 33 percent reduction from an incidence of 6.5 cases of diabetes per 100 person-years, with a 10 percent rate of loss to follow-up per year.
The time to the outcome was assessed with the use of life-table methods.19 Modified product-limit curves for the cumulative incidence of diabetes were compared with the use of the log-rank test. The estimated cumulative incidence at three years and the Greenwood estimate of the standard error were used to calculate the number of persons who would need to be treated in order to prevent one case of confirmed diabetes during a period of three years and the associated 95 percent confidence interval. Risk reduction, heterogeneity among strata, and interactions between treatment assignments and covariates were assessed by proportional-hazards regression. Fixed-effects models with the assumption of normally distributed errors20 were used to assess differences over time in body weight and plasma glucose and glycosylated hemoglobin values among the three groups.
STUDY COHORT AND FOLLOW-UP
Table 1.Base-Line Characteristics of the Study Participants.
From 1996 to 1999, we randomly assigned 3234 study participants to one of the three interventions (1082 to placebo, 1073 to metformin, and 1079 to the intensive lifestyle intervention). Base-line characteristics, including all measured risk factors for diabetes, were similar among the three study groups (Table 1).12 The participants were followed for an average of 2.8 years (range, 1.8 to 4.6). At the close of the study, 99.6 percent of the participants were alive, of whom 92.5 percent had attended a scheduled visit within the previous five months.
ADHERENCE TO INTERVENTIONS
Fifty percent of the participants in the lifestyle-intervention group had achieved the goal of weight loss of 7 percent or more by the end of the curriculum (at 24 weeks), and 38 percent had a weight loss of at least 7 percent at the time of the most recent visit; the proportion of participants who met the goal of at least 150 minutes of physical activity per week (assessed on the basis of logs kept by the participants) was 74 percent at 24 weeks and 58 percent at the most recent visit. Dietary change was assessed only at one year. Daily energy intake decreased by a mean (±SE) of 249±27 kcal in the placebo group, 296±23 kcal in the metformin group, and 450±26 kcal in the lifestyle-intervention group (P<0.001). Average fat intake, which was 34.1 percent of total calories at base line, dec reased by 0.8±0.2 percent in the placebo and metformin groups and by 6.6±0.2 percent in the lifestyle-intervention group (P<0.001). The proportion of participants who took at least 80 percent of the prescribed dose of the study medication was slightly higher in the placebo group than in the metformin group (77 percent vs. 72 percent, P<0.001). Ninety-seven percent of the participants taking placebo and 84 percent of those taking metformin were given the full dose of one tablet (850 mg in the case of metformin) twice a day; the remainder were given one tablet a day to limit side effects.
Figure 1.Changes in Body Weight (Panel A) and Leisure Physical Activity (Panel B) and Adherence to Medication Regimen (Panel C) According to Study Group.
Changes in weight and leisure physical activity in all three groups and adherence to the medication regimen in the metformin and placebo groups are shown in Figure 1. Participants assigned to the lifestyle intervention had much greater weight loss and a greater increase in leisure physical activity than did participants assigned to receive metformin or placebo. The average weight loss was 0.1, 2.1, and 5.6 kg in the placebo, metformin, and lifestyle-intervention groups, respectively (P<0.001).
INCIDENCE OF DIABETES
Figure 2.Cumulative Incidence of Diabetes According to Study Group.Table 2.Incidence of Diabetes.
The cumulative incidence of diabetes was lower in the metformin and lifestyle-intervention groups than in the placebo group throughout the follow-up period (Figure 2). The crude incidence was 11.0, 7.8, and 4.8 cases per 100 person-years for the placebo, metformin, and lifestyle-intervention groups, respectively (Table 2). The incidence of diabetes was 58 percent lower (95 percent confidence interval, 48 to 66 percent) in the lifestyle-intervention group and 31 percent lower (95 percent confidence interval, 17 to 43 percent) in the metformin group than in the placebo group. The incidence of diabetes was 39 percent lower (95 percent confidence interval, 24 to 51 percent) in the lifestyle-intervention group than in the metformin group. The results of all three pairwise group comparisons were statistically significant by the group-sequential log-rank test. None of these results were materially affected by adjustment for base-line characteristics. The estimated cumulative incidence of diabetes at three years was 28.9 percent, 21.7 percent, and 14.4 percent in the placebo, metformin, and lifestyle-intervention groups, respectively. On the basis of these rates, the estimated number of persons who would need to be treated for three years to prevent one case of diabetes during this period is 6.9 (95 percent confidence interval, 5.4 to 9.5) for the lifestyle intervention and 13.9 (95 percent confidence interval, 8.7 to 33.9) for metformin.
TREATMENT EFFECTS AMONG SUBGROUPS
Incidence rates and risk reductions within subgroups of participants and the results of tests of the homogeneity of risk reduction among subgroups are shown in Table 2; 95 percent confidence intervals for the subgroup data indicate the precision of the risk-reduction estimate for each stratum. The study had inadequate power to assess the significance of effects within the subgroups, nor were such tests planned. Significant heterogeneity indicates that treatment effects differed according to the values of the covariates. Treatment effects did not differ significantly according either to sex or to race or ethnic group (Table 2). The lifestyle intervention was highly effective in all subgroups. Its effect was significantly greater among persons with lower base-line glucose concentrations two hours after a glucose load than among those with higher base-line glucose values. The effect of metformin was less with a lower body-mass index or a lower fasting glucose concentration than with higher values for those variables. Neither interaction was explained by the other variable or by age. The advantage of the lifestyle intervention over metformin was greater in older persons and those with a lower body-mass index than in younger persons and those with a higher body-mass index.
Figure 3.Fasting Plasma Glucose Concentrations (Panel A) and Glycosylated Hemoglobin Values (Panel B) According to Study Group.Figure 4.Participants with Normal Plasma Glucose Values, According to Study Group.
In the first year, there was a similar reduction in the mean fasting plasma glucose values in the metformin and lifestyle-intervention groups, whereas the values rose in the placebo group (Figure 3). The values rose in parallel in all three groups in subsequent years. There was a similar temporal pattern in the values for glycosylated hemoglobin, except that the values in the metformin group were in between those in the lifestyle-intervention and placebo groups. Figure 4 shows the percentage of participants who had normal glucose concentrations (fasting values, post-load values, and both) at each annual examination. Metformin and the lifestyle intervention were similarly effective in restoring normal fasting glucose values, but the lifestyle intervention was more effective in restoring normal post-load glucose values.
Table 3.Adverse Events.
The rate of gastrointestinal symptoms was highest in the metformin group, and the rate of musculoskeletal symptoms was highest in the lifestyle-intervention group (Table 3). Hospitalization and mortality rates were unrelated to treatment. No deaths were attributed to the study intervention.
Our results support the hypothesis that type 2 diabetes can be prevented or delayed in persons at high risk for the disease. The incidence of diabetes was reduced by 58 percent with the lifestyle intervention and by 31 percent with metformin, as compared with placebo. These effects were similar in men and women and in all racial and ethnic groups. The intensive lifestyle intervention was at least as effective in older participants as it was in younger participants. The results of our study extend previous data showing that lifestyle interventions can reduce the incidence of diabetes7,8 and demonstrate the applicability of this finding to the ethnically and culturally diverse population of the United States. The risk reduction associated with the lifestyle intervention in our study was the same as that in a study conducted in Finland,8 and was higher than the reductions associated with diet (31 percent), exercise (46 percent), and diet plus exercise (42 percent) in a study in China.7
Our lifestyle intervention was systematic and intensive, with the study participants receiving detailed, individualized counseling. The study, however, was not designed to test the relative contributions of dietary chang es, increased physical activity, and weight loss to the reduction in the risk of diabetes, and the effects of these components remain to be determined.
The incidence of diabetes in our placebo group (11.0 cases per 100 person-years) was higher than we had anticipated6 and was higher than the incidence in observational studies,21 perhaps owing to the greater frequency of glucose testing or to the selection of persons at higher risk in our study. The incidence of diabetes in the placebo group was similar among racial and ethnic groups despite differences in these subgroups in observational, population-based studies.10 Racial and ethnic-group differences in the incidence of diabetes were presumably reduced in our study by the selection of persons who were overweight and had elevated fasting and post-load glucose concentrations — three of the strongest risk factors for diabetes.
Previous studies have not demonstrated that drugs used to treat diabetes are effective for its prevention, perhaps because of small samples and the lack of data on adherence to the prescribed regimens.5 In contrast, metformin was effective in our study, although less so than the lifestyle intervention. Metformin was less effective in persons with a lower base-line body-mass index or a lower fasting plasma glucose concentration than in those with higher values for these variables. The reduction in the average fasting plasma glucose concentration was similar in the lifestyle-intervention and metformin groups, but the lifestyle intervention had a greater effect than metformin on glycosylated hemoglobin, and a larger proportion of participants in the lifestyle-intervention group had normal post-load glucose values at follow-up. These findings are consistent with the observation that metformin suppresses endogenous glucose production, the main determinant of fasting plasma glucose concentrations.22
Rates of adverse events, hospitalization, and mortality were similar in the three groups, except that the rate of gastrointestinal symptoms was highest in the metformin group and the rate of musculoskeletal symptoms was highest in the lifestyle-intervention group. Thus, the interventions were safe in addition to being effective.
An estimated 10 million persons in the United States resemble the participants in the Diabetes Prevention Program in terms of age, body-mass index, and glucose concentrations, according to data from the third National Health and Nutrition Examination Survey.23 If the study's interventions were implemented among these people, there would be a substantial reduction in the incidence of diabetes. Ultimately, the benefits would depend on whether glucose concentrations could be maintained at levels below those that are diagnostic of diabetes and whether the maintenance of these lower levels improved the long-term outcome. These questions should be addressed by continued follow-up of the study participants and by analysis of the main secondary outcomes — reductions in risk factors for cardiovascular disease, in the proportion of participants with atherosclerosis, and in the proportion with cardiovascular disease, which is the leading cause of death among patients with type 2 diabetes.24,25
Optimal approaches to identifying candidates for preventive measures remain to be determined. Although elevation of either the fasting or the post-load glucose concentration strongly predicts diabetes,26,27 both were required for eligibility in this study. Whether the results would be similar in persons with an isolated elevation of the fasting or post-load glucose concentration or other risk factors for diabetes is likely but unknown.
In summary, our study showed that treatment with metformin and modification of lifestyle were two highly effective means of delaying or preventing type 2 diabetes. The lifestyle intervention was particularly effective, with one case of diabetes prevented per seven persons treated for three years. Thus, it should also be possible to delay or prevent the development of complications, substantially reducing the individual and public health burden of diabetes.
Supported by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, the Office of Research on Minority Health, the National Institute of Child Health and Human Development, and the National Institute on Aging; the Indian Health Service; the Centers for Disease Control and Prevention; the General Clinical Research Center Program, National Center for Research Resources; the American Diabetes Association; Bristol-Myers Squibb; and Parke-Davis.
Dr. Hamman owns stock in Bristol-Myers Squibb, which sells metformin in the United States.
We are indebted to the participants in the study for their dedication to the goal of preventing diabetes; to Lipha Pharmaceuticals for the metformin and placebo; to LifeScan, Health-O-Meter, Hoechst Marion Roussel, Merck-Medco Managed Care, Merck, Nike, Slim-Fast Foods, and Quaker Oats for materials, equipment, and medicines for concomitant conditions; and to McKesson BioServices, Mathews Media Group, and the Henry M. Jackson Foundation for support services provided under subcontract with the Coordinating Center.
The writing group (William C. Knowler, M.D., Dr.P.H., Elizabeth Barrett-Connor, M.D., Sarah E. Fowler, Ph.D., Richard F. Hamman, M.D., Dr.P.H., John M. Lachin, Sc.D., Elizabeth A. Walker, D.N.Sc., and David M. Nathan, M.D.) takes responsibility for the content of this article.
Address reprint requests to the Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, 6110 Executive Blvd., Suite 750, Rockville, MD 20852.
The members of the Diabetes Prevention Program Research Group are listed in the Appendix.
The following investigators were members of the Diabetes Prevention Program Research Group (asterisks indicate principal investigators, and daggers program coordinators): Pennington Biomedical Research Center — G.A. Bray,* I.W. Culbert,† C.M. Champagne, M.D. Crow, L. Dawson, B. Eberhardt, F.L. Greenway, F.G. Guillory, A.A. Hebert, M.L. Jeffirs, K. Joyce, B.M. Kennedy, J.C. Lovejoy, S. Mancuso, L.E. Melancon, L.H. Morris, L. Reed, J. Perault, K. Rau, D.H. Ryan, D.A. Sanford, K.G. Smith, L.L. Smith, S.R. Smith, J.A. St. Amant, M. Terry, E. Tucker, R.T. Tulley, P.C. Vicknair, D. Williamson, and J.J. Zachwieja; University of Chicago— D.A. Ehrmann,* M.J. Matulik,† B. Clarke, D.A. Collins, K.B. Czech, C. DeSandre, G. Geiger, S. Grief, B. Harding-Clay, R.M. Hilbrich, D. le Grange, M.R. McCormick, W.L. McNabb, K.S. Polonsky, N.P. Sauter, A.R. Semenske, K.A. Stepp, and J.A. Tobian; Jefferson Medical College — P.G. Watson,* J.T. Mendoza,† K.A. Smith,† J. Caro, B. Goldstein, C. Lark, L. Menefee, L. Murphy, C. Pepe, and J.M. Spandorfer; University of Miami — R.B. Goldberg,* P. Rowe,† J. Calles, P. Casanova, R.P. Donahue, H .J. Florez, A. Giannella, G. Larreal, V. McLymont, J. Mendez, P. O'Hara, J. Ojito, R. Prineas, and P.G. Saab; The University of Texas Health Science Center— S.M. Haffner,* M.G. Montez,† C. Lorenzo, H. Miettinen, C.M. Mobley, L.A. Mykkanen, and M.M. Rozek; University of Colorado — R.F. Hamman,* P.V. Nash,† L. Testaverde,† D.R. Anderson, L.B. Ballonoff, A. Bouffard, B.N. Calonge, M. Farago, W.J. Georgitis, J.O. Hill, S.R. Hoyer, B.T. Jortberg, J.A. Merenich, M. Miller, J.G. Regensteiner, H.M. Seagle, C.M. Smith, S.C. Steinke, and B. VanDorsten; Joslin Diabetes Center — E.S. Horton,* K.E. Lawton,† R.A. Arky, M. Bryant, J.P. Burke, E. Caballero, K.M. Callaghan, D. Devlin, T. Franklin, O.P. Ganda, A.E. Goebel-Fabbri, M. Harris, S.D. Jackson, A.M. Jacobsen, L.M. Kula, M. Kocal, S. Ledbury, M.A. Malloy, C. Mullooly, M. Nicosia, C.F. Oldmixon, J. Pan, C. Pomposelli, M. Quitongan, S. Rubtchinsky, D. Schweizer, E.W. Seely, D. Simonson, F. Smith, C.G. Solomon, J. Tyson, and J. Warram; University of Washington and Veterans Affairs Puget Sound Health Care System — S.E. Kahn,* B.K. Montgomery,† M. Alger, E. Allen, T. Barrett, D. Bhanji, J. Cowan, J. Cullen, W.Y. Fujimoto, B. Katz, R.H. Knopp, E.W. Lipkin, M. Marr, B.S. McCann, J.P. Palmer, R.S. Schwartz, and D. Uyema; University of Tennessee — A.E. Kitabchi,* M.E. Murphy,† W.B. Applegate, M. Bryer-Ash, J.H. Coble, A. Crisler, G. Cunningham, A.W. Franklin, S.L. Frieson, D.L. Green, R. Imseis, C.L. Kennedy, H.C. Lambeth, K.A. Latif, L.C. Lichtermann, M.D. McIntyre, J.D. Nault, H. Oktaei, M.L. O'Toole, H. Ricks, L.M.K. Rutledge, S.C. Schussler, A.R. Sherman, C.M. Smith, J.E. Soberman, K.J. Stewart, D.L. VanBrunt, and B.J. Williams-Cleaves; Northwestern University Medical School — B.E. Metzger,* M.K. Johnson,† C. Behrends, M.L. Cook, M. Fitzgibbon, M.M. Giles, D. Heard, C. Johnson, D. Larsen, A. Lowe, M. Lyman, D. McPherson, M.E. Molitch, T. Pitts, R. Reinhart, S. Roston, and P.A. Schinleber; Massachusetts General Hospital — D.M. Nathan,* C. McKitrick,† K. Abbott, E. Anderson, L. Bissett, E. Cagliero, S. Crowell, L. Delahanty, S. Fritz, K. Hayward, E. Levina, T. Michel, D. Norman, J. O'Keefe, A. Poulos, L. Ronan, M. Rosal, M. Salerno, M. Schneider, C. Shagensky, B. Steiner, H. Turgeon, and A. Young; University of California, San Diego — J.M. Olefsky,* M.L. Carrion-Petersen,† E. Barrett-Connor, M. Beltran, K. Caenepeel-Mills, S.V. Edelman, R.O. Ford, J. Garcia, M. Hagerty, R.R. Henry, M. Hill, J. Horne, D. Leos, J. Matney, S. Mudaliar, G. Petersen, A. Pollard, W. Polonsky, S. Szerdi, J. Torio-Hurley, and K. Vejvoda; St. Luke's–Roosevelt Hospital — F.X. Pi-Sunyer,* J.E. Lee,† D.B. Allison, N. Agharanya, N.J. Aronoff, M. Baldo, S.T. Foo, S. Hagamen, C. Pal, K. Parkes, M. Pena, and G.E.H. Van Wye; Indiana University — D.G. Marrero,* M.S. Kukman-Kelly,† Y.F. Dotson, S.E. Fineberg, J.C. Guare, A. Hadden, B. Hills, J.M. Ignaut, M.A. Jackson, M.S. Kirkman, K. Mather, G. McAtee, B.D. Porter, M.J. Prince, and M.L. Wheeler; Medstar Research Institute — R.E. Ratner,* G. Youssef,† S. Shapiro,† A. Bonar, M. Bronsord, E. Brown, W.W. Cheatham, S. Cola, A. Comfort, G. Boggs, C. Eagle, C. Evans, E. Gorman, R. Johnson, C. Levetan, T. Kellum, M. Lagarda, A.K. Nair, M.D. Passaro, and W. Phillips; UCLA Medical School — M.F. Saad,* M. Budgett,† S. Fahmi,† S.D. Jinagouda,† B. Bernaba, S.L. Bodkin, V. Ciobanu, R. Commisso, C. Cosenza, T. Dinh, M. Gonzalez, A. Khan, D. Kumar, G. Lui, V. Mehta, A. Sharma, S. Soukiazian, K. Szamos, A. Tramanian, A. Vargas, and N. Zambrana; Washington University, St. Louis — N.H. White,* A.S. Santiago,† S. Das,† A.L. Brown, S. Dagogo-Jack, E.B. Fisher, E. Hurt, T. Jones, M. Kerr, L. Ryder, J.V. Santiago (deceased), and C. Wernimont; Johns Hopkins School of Medicine — C.D. Saudek,* V.L. Bradley,† T. Fowlkes,† H. Joseph,† F.L. Brancati, J.B. Charleston, J.M. Clark, K. Horak, D. Jiggetts, H. Mosley, R.R. Rubin, A. Samuels, K.J. Stewart, L. Thomas, and P. Williamson; University of New Mexico School of Medicine — D.S. Schade,* K.S. Adams,† L.F. Atler, A. Bland, D.A. Bowling, P.J. Boyle, M.R. Burge, L. Butler, J.L. Canady, L. Chai, K.M. Colleran, M. Guillen, Y. Gonzales, M. Gutierrez, D. Hornbeck, C. Johannes, P. Katz, C. King, E.N. Libby III, R. McCalman, D.A. Montoya, A. Rassam, S. Rubinchik, and W. Senter; Albert Einstein College of Medicine — H. Shamoon,* J.O. Brown,† J. Adames, E. Blanco, L. Cox, J.P. Crandall, H. Duffy, S. Engel, A. Friedler, T. Harroun, C.J. Howard-Century, S. Kloiber, N. Longchamp, D. Pompi, E. Violino, E.A. Walker, J. Wylie-Rosett, E. Zimmerman, and J. Zonszein; University of Pittsburgh — R.R. Wing,* M.K. Kramer,† S. Barr, M.A. Boraz, L. Clifford, R. Culyba, M. Frazier, R. Gilligan, L. Harris, S. Harrier, W. Henderson, S. Jeffries, G. Koenning, A.M. Kriska, K. Maholic, Q. Manjoo, M. Mullen, A. Noel, T.J. Orchard, A. Otto, L.N. Semler, C. Smith, M. Smith, V. Stapinski, J. Viteri, T. Wilson, K.V. Williams, and J. Zgibor; University of Hawaii— R.F. Arakaki,* R.W. Latimer,† N.K. Baker-Ladao, R.M. Beddow, R. Braginsky, M. Calizar, L.M. Dias, N. Durham, D.A. Dupont, L.L. Fukuhara, J. Inouye, M.K. Mau, K. Mikami, P. Mohideen, S.K. Odom, B. Sinkule-Kam, J.S. Tokunaga, R.U. Twiggs, C.Y. Wang, and J. Vita; Southwest American Indian Center for Diabetes Prevention— W.C. Knowler,* N.J. Cooeyate,† M.A. Hoskin,† C.A. Percy,† K.J. Acton, V.L. Andre, S. Antone, N.M. Baptisto, R. Barber, S. Begay, P.H. Bennett, M.B. Benson, S. Beyale, E.C. Bird, B.A. Broussard, M. Chavez, T.S. Dacawyma, M.S. Doughty, R. Duncan, C. Edgerton, J.M. Ghahate, M. Glass, D. Gohdes, W. Grant, R.L. Hanson, E. Horse, G. Hughte, L.E. Ingraham, M.C. Jackson, P.A. Jay, R.S. Kaskalla, D. Kessler, K.M. Kobus, J. Krakoff, C. Manus, T. Morgan, Y. Nashboo (deceased), J. Nelson, G.L. Pauk, S. Poirier, E. Polczynski, M. Reidy, J. Roumain, D.H. Rowse, R.J. Roy, S. Sangster, J. Sewemaenewa, D. Tonemah, C. Wilson, and M. Yazzie; George Washington University Biostatistics Center — S. Fowler,* T. Brenneman,† S. Abebe, R. Bain, J. Bamdad, J. Callaghan, S.L. Edelstein, Y. Gao, K.L. Grimes, N. Grover, K. Hirst, S. Jones, T.L. Jones, R.J. Katz, J.M. Lachin, R. Orlosky, C.E. Stimpson, C. Suiter, M.G. Temprosa, and F.E.M. Walker-Murray; National Institute of Diabetes and Digestive and Kidney Diseases Program Office — S. Garfield,† R. Eastman, and J. Fradkin; National Institute on Aging — R. Andres; Centers for Disease Control and Prevention — M.M. Engelgau, K.M. Venkat Narayan, and D.F. Williamson; University of Michigan — W.H. Herman; Central Biochemistry Laboratory (University of Washington) — S.M. Marcovina,* A. Aldrich, and W.L. Chandler; Central ECG Reading Center (Wake Forest University) — P.M. Rautaharju,* N.T. Pemberton, R. Prineas, F.S.R. Rautaharju, and Z. Zhang; Nutrition Coding Center (University of South Carolina) — E.J. Mayer-Davis,* T. Costacou, M. Martin, and K.L. Sparks; Central Carotid Ultrasound Unit (New England Medical Center) — D.H. O'Leary,* L.R.C. Funk, K.A. O'Leary, and J.F. Polak; CT-Scan Reading Unit (University of Colorado) — E.R. Stamm* and A.L. Scherzinger; Lifestyle Resource Core (University of Pittsburgh) — R.R. Wing,* B.P. Gillis, C. Huffmyer, A.M. Kriska, and E.M. Venditti; Medication Resource Workgroup (Albert Einstein College of Medicine) — E.A. Walker* and T. Harroun; Quality of Well Being Reading Unit (University of California, San Diego) — T.G. Ganiats,* E.J. Groessl, P.R. Beerman, K.M. David, R.M. K aplan, and W.J. Sieber; Data Monitoring Board — S.M. Genuth (chair), G.F. Cahill, F.L. Ferris III, J.R. Gavin III, J.B. Halter, and J. Wittes; Ancillary Studies Subcommittee — R.R. Henry and S.M. Haffner (chairs); Behavioral Scientists — R.R. Rubin (chair); Clinic Operations — B.K. Montgomery (chair); Concomitant Conditions — R.E. Ratner (chair); Economic Evaluation — W.H. Herman (chair); Interventions — S.E. Kahn, J.V. Santiago (deceased), and J. Olefsky (chairs); Lifestyle Advisory Group — R.R. Wing (chair); Outcomes — C. Saudek (chair); Outcomes Classification — R.E. Ratner (chair); Program Coordinators Subcommittee — M. Montez and K. Kramer (chairs); Protocol Oversight — R.F. Hamman (chair); Publications and Presentations — W.C. Knowler (chair); Quality Control — R.B. Goldberg (chair); Recruitment — W.Y. Fujimoto (chair); Recruitment Coordinators Subcommittee — J. Charleston (chair); Retention — R.R. Rubin (chair); Screening and Eligibility — R.F. Hamman (chair); Study Chair and Vice Chair — D.M. Nathan and R.F. Hamman.
Lark helps you eat better, move more, stress less, and improve your overall wellness. Lark’s digital coach is available 24/7 on your smartphone to give you personalized tips, recommendations, and motivation to lose weight and prevent chronic conditions like diabetes.